| Entry |
| ||||||
|---|---|---|---|---|---|---|---|
| Name | Avacopan (JAN/USAN/INN); Tavneos (TN) | ||||||
| Product | TAVNEOS (ChemoCentryx) | ||||||
| Formula | C33H35F4N3O2 | ||||||
| Exact mass | 581.2665 | ||||||
| Mol weight | 581.6435 | ||||||
| Structure |  | ||||||
| Class | Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate | ||||||
| Remark |
| ||||||
| Efficacy | Anti-inflammatory, Complement C5a receptor antagonist | ||||||
| Comment | Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis | ||||||
| Target | C5AR1 (CD88) [HSA:728] [KO:K04010] | ||||||
| Pathway |
| ||||||
| Metabolism | Enzyme: CYP3A4 [HSA:1576] | ||||||
| Interaction | |||||||
| Brite | Therapeutic category of drugs in Japan [BR:br08301] 3 Agents affecting metabolism 39 Other agents affecting metabolism 399 Miscellaneous 3999 Others D11093 Avacopan (JAN/USAN/INN) Drug groups [BR:br08330] Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate D11093 Avacopan Target-based classification of drugs [BR:br08310] Cell surface molecules and ligands Other cell surface molecules CD molecules C5AR1 (CD88) D11093 Avacopan (JAN/USAN/INN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D11093 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D11093 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D11093 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D11093 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D11093 | ||||||
| Other DBs |
| ||||||
| KCF data | ATOM 42 1 N1y N 15.8200 -18.9700 2 C1x C 15.8200 -20.3700 3 C1x C 17.0324 -21.0700 4 C1x C 18.2449 -20.3700 5 C1y C 18.2449 -18.9700 6 C1y C 17.0324 -18.2700 7 C5a C 14.6076 -18.2700 8 C8y C 13.4121 -18.9604 9 C8y C 12.2247 -18.2749 10 C8x C 11.0123 -18.9750 11 C8x C 11.0124 -20.3750 12 C8x C 12.1997 -21.0604 13 C8y C 13.4121 -20.3604 14 X F 14.6496 -21.0749 15 C1a C 12.2246 -16.8702 16 O5a O 14.6075 -16.8702 17 C8y C 17.0324 -16.8702 18 C8x C 18.2280 -16.1797 19 C8x C 18.2278 -14.7797 20 C8y C 17.0153 -14.0799 21 C8x C 15.8198 -14.7703 22 C8x C 15.8199 -16.1703 23 N1b N 17.0152 -12.6700 24 C1y C 18.2237 -11.9722 25 C1x C 19.5444 -12.3607 26 C1x C 20.3250 -11.2257 27 C1x C 19.4868 -10.1326 28 C1x C 18.1881 -10.5920 29 C5a C 19.4760 -18.2590 30 N1b N 20.6812 -18.9547 31 C8y C 21.8635 -18.2719 32 O5a O 19.4757 -16.8701 33 C8x C 23.0575 -18.9612 34 C8y C 24.2699 -18.2612 35 C8y C 24.2699 -16.8612 36 C8x C 23.0760 -16.1719 37 C8x C 21.8635 -16.8719 38 C1a C 25.4934 -16.1546 39 C1d C 25.5012 -18.9722 40 X F 26.6967 -19.6625 41 X F 26.2012 -17.7597 42 X F 24.8012 -20.1846 BOND 46 1 1 2 1 2 2 3 1 3 3 4 1 4 4 5 1 5 5 6 1 6 1 6 1 7 1 7 1 8 7 8 1 9 8 9 2 10 9 10 1 11 10 11 2 12 11 12 1 13 12 13 2 14 8 13 1 15 13 14 1 16 9 15 1 17 7 16 2 18 6 17 1 #Up 19 17 18 2 20 18 19 1 21 19 20 2 22 20 21 1 23 21 22 2 24 17 22 1 25 20 23 1 26 23 24 1 27 24 25 1 28 25 26 1 29 26 27 1 30 27 28 1 31 24 28 1 32 5 29 1 #Up 33 29 30 1 34 30 31 1 35 29 32 2 36 31 33 2 37 33 34 1 38 34 35 2 39 35 36 1 40 36 37 2 41 31 37 1 42 35 38 1 43 34 39 1 44 39 40 1 45 39 41 1 46 39 42 1 |